Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Current treatment with insulin NPH or glargine

• The selection of the subjects will be at the discretion of the individual physician

Exclusion Criteria:

• Current treatment with insulin detemir

• Previous enrolment in this study

• Hypersensitivity to insulin detemir or to any of the excipients.

• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months